Jefferies sees a buying opportunity in this biotech stock Apr 17, 2026 09:00PM
Wolfe Research Starts Zealand Pharma A/S (ZEAL:DC) (ZEAL) at Outperform Mar 26, 2026 05:34AM
William Blair Downgrades Zealand Pharma A/S (ZEAL:DC) (ZEAL) to Market Perform, Removed from Analyst Conviction List Mar 6, 2026 07:06AM
Cantor Fitzgerald Downgrades Zealand Pharma A/S (ZEAL:DC) (ZEAL) to Neutral Mar 6, 2026 06:23AM
Zealand Pharma reports 71.5 million shares outstanding after warrant exercise Dec 31, 2025 11:05AM


Dec 11, 2025 04:01PM Zealand Pharma raises share capital through employee warrant exercise
Sep 23, 2025 05:12AM UBS Starts Zealand Pharma A/S (ZEAL:DC) (ZEAL) at Buy
Jul 24, 2025 06:33AM Wells Fargo Starts Zealand Pharma A/S (ZEAL:DC) (ZEAL) at Overweight
Jul 8, 2025 03:14AM Barclays Starts Zealand Pharma A/S (ZEAL:DC) (ZEAL) at Overweight
Jul 1, 2025 06:24AM BNP Paribas Exane Starts Zealand Pharma A/S (ZEAL:DC) (ZEAL) at Outperform
Jun 18, 2025 11:31AM Zealand Pharma (ZEAL) announces positive topline results from Phase 1b study on dapiglutide
May 23, 2025 06:47AM Cantor Fitzgerald Reiterates Overweight Rating on Zealand Pharma A/S (ZEAL)
May 20, 2025 04:14AM Zealand Pharma A/S (ZEAL:DC) (ZEAL) PT Lowered to DKK485 at Deutsche Bank
Mar 21, 2025 03:06AM Morgan Stanley Upgrades Zealand Pharma A/S (ZEAL:DC) (ZEAL) to Overweight
Mar 20, 2025 12:00PM Zealand Pharma (ZEAL) increases its share capital as a result of the exercise of employee warrants
Feb 28, 2025 12:39AM William Blair Starts Zealand Pharma A/S (ZEAL) at Market Perform
Jan 24, 2025 07:01AM Cantor Fitzgerald Reiterates Overweight Rating on Zealand Pharma A/S (ZEAL:DC) (ZEAL)
Dec 19, 2024 02:59PM Zealand Pharma (ZEAL) Receives FDA CRL for the glepaglutide New Drug Application
Oct 8, 2024 07:00PM Zealand Pharma (ZEAL) receives CRL for part 1 of NDA for dasiglucagon
Oct 2, 2024 10:45AM Deutsche Bank Starts Zealand Pharma A/S (ZEAL:DC) (ZEAL) at Hold
Sep 9, 2024 11:02AM Zealand Pharma (ZEAL) announces positive topline results from 13-week Phase 1b multiple ascending dose clinical trial with GLP-1/GLP-2 receptor dual agonist dapiglutide
Aug 16, 2024 11:00AM Zealand Pharma A/S (ZEAL:DC) (ZEAL) PT Raised to DKK1,106 at Goldman Sachs
Jun 25, 2024 02:44PM Zealand Pharma (ZEAL) announces upsizing of previously announced equity offering from approximately USD 900 million / DKK 6.257 billion to USD 1 billion / DKK 7 billion
Jun 25, 2024 11:03AM Zealand Pharma (ZEAL) launches equity offering of new shares raising gross proceeds of approximately USD 900 million / DKK 6.257 billion
Jun 20, 2024 11:39AM Zealand Pharma (ZEAL) reports positive topline results from the Phase 1b 16-week multiple ascending dose clinical trial with long-acting amylin analog petrelintide